Healthcare diagnostics company QuidelOrtho (NASDAQ: QDEL) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.8% year on year to $630.9 million. On the other hand, the company’s full-year revenue guidance of $2.56 billion at the midpoint came in 5.4% below analysts’ estimates. Its non-GAAP profit of $0.13 per share was significantly above analysts’ consensus estimates.

Is now the time to buy QDEL? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

QuidelOrtho’s second quarter results were met with a negative market reaction, reflecting investor concern over significant challenges in key markets. While management pointed to solid demand in North America and strong commercial execution in regions like Japan and Latin America, CEO Brian J. Blaser cited a “softer respiratory environment” and pronounced weakness in China as primary factors impacting performance. The company’s leadership was notably cautious, highlighting that China revenue fell sharply due to uncertainty around new in-vitro diagnostics (IVD) pricing guidelines, and that respiratory testing demand has softened compared to the prior year.

Looking forward, management’s updated guidance is shaped by persistent headwinds in China and a more conservative stance on the upcoming respiratory season. CFO Micah Young emphasized a “disciplined approach” to forecasting, noting that the company is modeling for continued muted activity in respiratory testing and assuming no near-term recovery in China. Blaser explained, “We are assuming the first-half softness continues and have modeled our second-half respiratory revenues accordingly,” while reiterating the company’s focus on cost management and cash flow improvements despite external uncertainties.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to growth outside China, operational improvements, and the strategic launch of a new molecular diagnostics platform.

• Underlying business strength outside China: Management highlighted 6% year-over-year revenue growth outside of China, with labs, immunohematology, and Triage point-of-care products all showing solid demand. North America and the JPAC region (Japan and Asia-Pacific) were strong contributors, demonstrating customer retention and effective commercial execution despite geographic headwinds elsewhere.
• China revenue under pressure: The company experienced a 23% decline in China revenue, which management attributed to uncertainty over draft IVD pricing guidelines. The evolving policy led to customers reducing inventory and delaying purchases, which Blaser described as a material headwind. The company is focusing on protecting its installed base and adapting its go-to-market approach in anticipation of further regulatory shifts.
• Operational improvement initiatives: Adjusted EBITDA margin increased by 310 basis points, which management attributed to disciplined expense management and productivity gains. Initiatives included prioritizing high-return investments, rationalizing costs, and improving working capital efficiency. CFO Micah Young identified cash conversion and leverage reduction as top priorities moving forward.
• Neulixa platform launch: The acquisition and launch of the Neulixa (formerly Lex) point-of-care molecular platform was a major milestone. Management emphasized the platform’s potential for rapid, accurate diagnostics and a scalable menu of tests. Early customer feedback has been positive, and the company expects increasing placements as the respiratory season progresses.
• Respiratory market softness: Management noted that respiratory testing volumes are down compared to last year, citing lower positivity rates and weaker indicators from the Southern Hemisphere. The company is taking a more prudent approach to forecasting this segment, modeling for a continuation of current trends rather than a typical seasonal uptick.

Drivers of Future Performance

QuidelOrtho’s outlook hinges on persistent China challenges, a cautious respiratory market approach, and ongoing operational efficiency efforts.

• China market uncertainty persists: Management expects continued disruption in China due to pending IVD pricing regulations, with customers likely to maintain lower inventories and cautious purchasing patterns. The company is adapting its commercial strategy and cost structure to mitigate the impact, but acknowledges that visibility remains limited for the remainder of the year.
• Respiratory season assumptions are conservative: The guidance assumes respiratory testing volumes will remain at the lower end of historical ranges, reflecting weak current indicators and a lack of rebound in early data from both the U.S. and the Southern Hemisphere. Management does not anticipate a typical seasonal uptick, which could constrain revenue growth in the second half.
• Operational discipline and cost focus: CFO Micah Young identified improving cash conversion, optimizing capital allocation, and reducing leverage as central to the company’s strategy. Initiatives include cost structure improvements, instrument investment optimization, and tighter working capital management, all aimed at strengthening the balance sheet and supporting long-term profitability.

Catalysts in Upcoming Quarters

Going forward, our analyst team will be monitoring (1) the pace of adoption and customer utilization of the Neulixa platform as it launches into the respiratory season, (2) further developments and finalization of the IVD pricing guidelines in China and how customers adjust purchasing patterns in response, and (3) the company’s progress on operational improvements, particularly around cash conversion and leverage reduction. Execution on these fronts will be critical for assessing the path to sustainable growth.

QuidelOrtho currently trades at $12.54, down from $16.32 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

High Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.